Balanced secretion of anti-CEA × anti-CD3 diabody chains using the 2A self-cleaving peptide maximizes diabody assembly and tumor-specific cytotoxicity

Gene Therapy

Volumn 24, Issue 4, 2017, Pages 208-214

  Molgaard K ^a   Compte, M ^b   Nunez Prado N ^a   Harwood, S L ^a   Sanz, L ^b   Alvarez Vallina, L ^a  

^a AARHUS UNIVERSITY   (Denmark)

^b HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARCINOEMBRYONIC ANTIGEN; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY; CD3 ANTIBODY; F2A SELF CLEAVING PEPTIDE; MYC PROTEIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG; BISPECIFIC ANTIBODY; CD27 ANTIGEN; CD3 ANTIGEN; PEPTIDE;

ADOPTIVE TRANSFER; ANTIBODY PRODUCTION; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXICITY; EMBRYO; ENHANCER REGION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPRESSION VECTOR; FEMALE; FOOT AND MOUTH DISEASE VIRUS; GENE CONSTRUCT; HEK293 CELL LINE; HELA CELL LINE; HUMAN; HUMAN CELL; INTERNAL RIBOSOME ENTRY SITE; NONHUMAN; OPEN READING FRAME; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ASSEMBLY; PROTEIN CLEAVAGE; T LYMPHOCYTE ACTIVATION; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; JURKAT CELL LINE; LYMPHOCYTE ACTIVATION; NEOPLASMS; PROCEDURES; T LYMPHOCYTE;

ANTIBODIES, BISPECIFIC; ANTIGENS, CD27; ANTIGENS, CD3; CARCINOEMBRYONIC ANTIGEN; CYTOTOXICITY, IMMUNOLOGIC; FOOT-AND-MOUTH DISEASE VIRUS; HUMANS; IMMUNOTHERAPY; JURKAT CELLS; LYMPHOCYTE ACTIVATION; NEOPLASMS; PEPTIDES; SINGLE-CHAIN ANTIBODIES; T-LYMPHOCYTES;

EID: 85010871679     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2017.3     Document Type: Article

References (33)

1. Alvarez-Vallina L. Genetic approaches for antigen-selective cell therapy. Curr Gene Ther 2001; 1: 385-397.
2. Sanz L, Blanco B, Alvarez-Vallina L. Antibodies and gene therapy: teaching old ? magic bullets? new tricks. Trends Immunol 2004; 25: 85-91.
3. Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008; 321: 974-977.
4. Handgretinger R, Zugmaier G, Henze G, Kreyenberg H, Lang P, von Stackelberg A. Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-Transplant relapsed acute lymphoblastic leukemia. Leukemia 2011; 25: 181-184.
5. Topp MS, Kufer P, Gokbuget N, Goebeler M, Klinger M, Neumann S, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapyrefractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 2011; 29: 2493-2498.
6. Topp MS, Gökbuget N, Stein AS, Zugmaier G, O?Brien S, Bargou RC, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-Arm, phase 2 study. Lancet Oncol 2015; 16: 57-66.
7. Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 2014; 371: 1507-1517.
8. Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 2015; 385: 517-528.
9. Cuesta ÁM, Sainz-Pastor N, Bonet J, Oliva B, Álvarez-Vallina L. Multivalent antibodies: when design surpasses evolution. Trends Biotechnol 2010; 28: 355-362.
10. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 2007; 25: 267-296.
11. Blanco B, Holliger P, Vile RG, Alvarez-Vallina L. Induction of human T lymphocyte cytotoxicity and inhibition of tumor growth by tumor-specific diabody-based molecules secreted from gene-modified bystander cells. J Immunol 2003; 171: 1070-1077.
12. Compte M, Blanco B, Serrano F, Cuesta AM, Sanz L, Bernad A, et al. Inhibition of tumor growth in vivo by in situ secretion of bispecific anti-CEA x anti-CD3 diabodies from lentivirally transduced human lymphocytes. Cancer Gene Ther 2007; 14: 380-388.
13. Compte M, Cuesta AM, Sánchez-Martín D, Alonso-Camino V, Vicario JL, Sanz L, et al. Tumor immunotherapy using gene-modified human mesenchymal stem cells loaded into synthetic extracellular matrix scaffolds. Stem Cells 2009; 27: 753-760.
14. Compte M, Alonso-Camino V, Santos-Valle P, Cuesta AM, Sánchez-Martín D, López MR, et al. Factory neovessels: engineered human blood vessels secreting therapeutic proteins as a new drug delivery system. Gene Therapy 2010; 17: 745-751.
15. Compte M, Alvarez-Cienfuegos A, Nuñez-Prado N, Sainz-Pastor N, Blanco-Toribio A, Pescador N, et al. Functional comparison of single-chain and two-chain anti-CD3-based bispecific antibodies in gene immunotherapy applications. Oncoimmunology 2014; 3: e28810.
16. Hennecke M, Kwissa M, Metzger K, Oumard A, Kröger A, Schirmbeck R, et al. Composition and arrangement of genes define the strength of IRES-driven translation in bicistronic mRNAs. Nucleic Acids Res 2001; 29: 3327-3334.
17. Ryan MD, King AM, Thomas GP. Cleavage of foot-And-mouth disease virus polyprotein is mediated by residues located within a 19 amino acid sequence. J Gen Virol 1991; 72: 2727-2732.
18. De Felipe P. Skipping the co-expression problem: the new 2A 'CHYSEL' technology. Genet Vaccines Ther 2004; 2: 13.
19. Donnelly ML, Gani D, Flint M, Monaghan S, Ryan MD. The cleavage activities of aphthovirus and cardiovirus 2A proteins. J Gen Virol 1997; 78: 13-21.
20. Sanchez-Martin D, Cuesta AM, Fogal V, Ruoslahti E, Alvarez-Vallina L. The multicompartmental p32/gClqR as a new target for antibody-based tumor targeting strategies. J Biol Chem 2011; 286: 5197-5203.
21. Acqua WD, Goldman ER, Eisenstein E, Mariuzza RAA. Mutational analysis of the binding of two different proteins to the same. Methods 1996; 2960: 9667-9676.
22. Fang J, Qian J-J, Yi S, Harding TC, Tu GH, VanRoey M, et al. Stable antibody expression at therapeutic levels using the 2A peptide. Nat Biotechnol 2005; 23: 584-590.
23. Goedhart J, van Weeren L, Adjobo-Hermans MJW, Elzenaar I, Hink MA, Gadella TW Jr. Quantitative co-expression of proteins at the single cell level - Application to a multimeric FRET sensor. PLoS One 2011; 6: e27321.
24. Arber C, Abhyankar H, Heslop HE, Brenner MK, Liu H, Dotti G, et al. The immunogenicity of virus-derived 2A sequences in immunocompetent individuals. Gene Therapy 2013; 20: 958-962.
25. Saenz del Burgo L, Compte M, Aceves M, Hernández RM, Sanz L, Álvarez-Vallina L, et al. Microencapsulation of therapeutic bispecific antibodies producing cells: immunotherapeutic organoids for cancer management. J Drug Target 2015; 23: 170-179.
26. Blanco B, Holliger P, Alvarez-Vallina L. Autocrine costimulation: tumor-specific CD28-mediated costimulation of T cells by in situ production of a bifunctional B7-Anti-CEA diabody fusion protein. Cancer Gene Ther 2002; 9: 275-281.
27. Tsai AK, Davila E. Producer T cells: using genetically engineered T cells as vehicles to generate and deliver therapeutics to tumors. Oncoimmunology 2016; 5: e1122156.
28. Iwahori K, Kakarla S, Velasquez MP, Yu F, Yi Z, Gerken C, et al. Engager T cells: a new class of antigen-specific T cells that redirect bystander T cells. Mol Ther 2015; 23: 171-178.
29. Velasquez MP, Torres D, Iwahori K, Kakarla S, Arber C, Rodriguez-Cruz T, et al. T cells expressing CD19-specific engager molecules for the immunotherapy of CD19-positive malignancies. Sci Rep 2016; 6: 27130.
30. Liu X, Barrett DM, Jiang S, Fang C, Kalos M, Grupp SA, et al. Improved anti-leukemia activities of adoptively transferred T cells expressing bispecific T-cell engager in mice. Blood Cancer J 2016; 6: e430.
31. Kasuya K, Shimazu M, Suzuki M, Itoi T, Aoki T, Tsuchida A. Bispecific anti-HER2 and CD16 single-chain antibody production prolongs the use of stem cell-like cell transplantation against HER2-overexpressing cancer. Int J Mol Med 2010; 25: 209-215.
32. Sanz L, Garcia-Bermejo L, Blanco FJ, Kristensen P, Feijoo M, Suarez E, et al A novel cell binding site in the coiled-coil domain of laminin involved in capillary morphogenesis. EMBO J 2003; 22: 1508-1517.
33. Sanz L, Kristensen P, Russell SJ, Ramirez Garcia JR, Alvarez-Vallina L. Generation and characterization of recombinant human antibodies specific for native laminin epitopes: potential application in cancer therapy. Cancer Immunol Immunother 2001; 50: 557-565.